PLUR vs SABS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SABS Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SAB Biotherapeutics, Inc. Common Stock (SABS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while PLUR counters with relative strength in Valuation. Fundamentally, PLUR trades at 3.6x Forward P/E with -2454.5% operating margin (-15.8% YoY revenue) versus SABS at N/M Forward P/E and 0.0% operating margin (-62.4% YoY). In options structure, PLUR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SABS sits in SURGE (17th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PLUR Revenue | SABS Revenue | PLUR Op. Margin | SABS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -65800.0% | N/A | PLUR |
| FY2020 | $0M | $60M | -128156.5% | 37.2% | SABS |
| FY2021 | N/A | $60M | N/A | -22.0% | SABS |
| FY2022 | $0M | $20M | -17774.8% | -121.0% | SABS |
| FY2023 | $0M | $0M | -9493.4% | -1700.6% | SABS |
| FY2024 | $0M | $0M | -6796.9% | -3244.9% | SABS |
| FY2025 | $0M | N/A | -1659.9% | N/A | PLUR |
| FY2026 | $0M | N/A | -2454.5% | N/A | PLUR |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PLUR | SABS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.1M | $266.7M | Larger Scale | SABS |
| Trailing P/E Ratio Valuation | 3.6x | N/M | Lower Multiple | PLUR |
| Forward P/E Ratio Valuation | 3.6x | N/M | Lower Multiple | PLUR |
| Revenue Growth (YoY) Growth | -15.8% | -62.4% | Higher Growth | PLUR |
| Operating Margin (TTM) Profitability | -2454.5% | 0.0% | Higher Margin | SABS |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -1022.0% | -42.8% | Higher ROE | SABS |
| 52-Week Range Position Momentum | 2% ($1โ$5) | 18% ($2โ$5) | Stronger Trend | SABS |
| Beta / 30D Volatility Risk Regime | 0.80ฮฒ ยท 102% Vol | 1.28ฮฒ ยท 76% Vol | Lower Realized Risk | SABS |
| Unified Institutional Score Composite Signal | 28.8 / 100 (SELL) | 32.4 / 100 (SELL) | Higher Composite | SABS |